M
Michael J. Jamieson
Researcher at University of Texas Health Science Center at San Antonio
Publications - 17
Citations - 952
Michael J. Jamieson is an academic researcher from University of Texas Health Science Center at San Antonio. The author has contributed to research in topics: Population & Blood pressure. The author has an hindex of 8, co-authored 16 publications receiving 923 citations. Previous affiliations of Michael J. Jamieson include University of Texas System & Pfizer.
Papers
More filters
Journal ArticleDOI
From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report
Morteza Naghavi,Erling Falk,Harvey S. Hecht,Michael J. Jamieson,Sanjay Kaul,Daniel S. Berman,Zahi A. Fayad,Matthew J. Budoff,John A. Rumberger,Tasneem Z. Naqvi,Leslee J. Shaw,Ole Faergeman,Jay N. Cohn,Raymond D. Bahr,Wolfgang Koenig,Jasenka Demirovic,Dan E. Arking,Victoria L. M. Herrera,Juan J. Badimon,James A. Goldstein,Yoram Rudy,Juhani Airaksinen,Robert S. Schwartz,Ward A. Riley,Robert A. Mendes,Pamela S. Douglas,Prediman K. Shah +26 more
TL;DR: The Screening for Heart Attack Prevention and Education (SHAPE) Task Force presents a new practice guideline for cardiovascular screening in the asymptomatic at-risk population, calling for noninvasive screening of all asymptonomatic men 45‐75 years of age and asymPTomatic women 55‐75years of age to detect and treat those with subclinical atherosclerosis.
Journal ArticleDOI
The effect of iontophoresis on the cutaneous vasculature : evidence for current-induced hyperemia
Matthias Grossmann,Michael J. Jamieson,Dean L. Kellogg,Wojciech A. Kosiba,Pablo E. Pergola,Craig G. Crandall,Alexander M. M. Shepherd +6 more
TL;DR: Cutaneous vascular responses to iontophoresis comprise nonspecific, current-induced hyperemia and specific effects of the administered agent, including nitrite, which appears to cause muscarinic and current- induced dilatation.
Journal ArticleDOI
Effects of High-Dose Atorvastatin in Patients ≥65 Years of Age With Acute Coronary Syndrome (from the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering [MIRACL] Study)
TL;DR: The MIRACL study as mentioned in this paper randomized 3,086 patients to 16 weeks of 80 mg/day of atorvastatin or placebo 24 to 96 hours after acute coronary syndromes (ACSs) and demonstrated significant decreases in the combined primary end point (nonfatal acute myocardial infarction, resuscitated cardiac arrest, recurrent symptomatic myocardical ischemia).
Journal ArticleDOI
Improved Attainment of Blood Pressure and Cholesterol Goals Using Single-Pill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial
John M. Flack,Ronald G. Victor,Karol E. Watson,Keith C. Ferdinand,Elijah Saunders,Lisa Tarasenko,Michael J. Jamieson,Harry Shi,Pia Bruschi +8 more
TL;DR: Single-pill amlodipine/atorvastatin therapy was well tolerated and effectively targeted HTN and dyslipidemia in this population of African Americans who were at risk of cardiovascular disease.
Journal ArticleDOI
Evaluation of the IITC tail cuff blood pressure recorder in the rat against intraarterial pressure according to criteria for human devices
Michael J. Jamieson,Gary M. Gonzales,Thomas I. Jackson,Steven M. Koerth,William F. Romano,Dun Xian Tan,Frank Castillon,Michael H. Skinner,Matthias Grossmann,Alexander M. M. Shepherd +9 more
TL;DR: Findings do not support the manufacturer's guarantee of tail-cuff readings within "5 mm Hg of intraarterial," and inaccuracy and unreliability of devices intended for laboratory animal use have considerable scientific, fiscal, and ethical implications.